Skip to main content

Table 2 Mitotic figure distribution and the effect on the M.I. in C2C12 cells treated with doxorubicin

From: Combined study on clastogenic, aneugenic and apoptotic properties of doxorubicin in human cells in vitro

Chemical compound (μg ml−1) Total mitotic cells Prophases (%)
Mean ± SE
Metaphases (%)
Mean ± SE
Ana-telophases (%)
Mean ± SE
Total abnormal mitotic cells (%)
Mean ± SE
Total abnormal metaphases (%)
Mean ± SE
Mitotic Index (%)
Mean ± SE
0 1436 24
1.69 ± 0.25
474
32.88 ± 2.03
938
65.44 ± 1.78
152
10.51 ± 1.12
149
10.51 ± 1.07
5.86
5.87 ± 0.57
DOX 0.05 658 5
0.79* ± 0.79
159
24.15* ± 0.49
494
75.07* ± 0.31
477
72.69* ± 5.54
112
17.04* ± 0.32
1.34
1.34* ± 0.03
DEM 0.005 650 9
1.38* ± 0.06
425
64.85* ± 7.57
216
33.77* ± 7.62
409
62.49* ± 6.20
385
58.78* ± 6.46
2.14
2.14* ± 0.07
  1. DOX doxorubicin, DEM demecolcine was used as positive control, M.I. Mitotic Index, SE standard error
  2. * p ≤ 0.0001 in comparison with control (G-test)